NXTC Q4 2022 Earnings — NextCure, Inc. Revenue & Financial Results | Market Cap Arena

NXTCNextCure, Inc.

$36M

Q4 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$18M

Net Income

-$17M

EPS (Diluted)

$-7.47

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$9M

Free Cash Flow

-$10M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$184M

Total Liabilities

$17M

Stockholders' Equity

$168M

Cash & Equivalents

$27M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$18M	-$17M	-4.1%
Net Income	-$17M	-$17M	-2.1%